Detalhe da pesquisa
1.
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(8): 1414-1424, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325171
2.
Lenalidomide after stem-cell transplantation for multiple myeloma.
N Engl J Med
; 366(19): 1770-81, 2012 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22571201
3.
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
Haematologica
; 99(1): 111-5, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24077846
4.
Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.
Biol Blood Marrow Transplant
; 18(5): 690-7, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21875505
5.
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Haematologica
; 97(4): 579-85, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22102709
6.
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
Biol Blood Marrow Transplant
; 17(9): 1395-403, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21296675
7.
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
Biol Blood Marrow Transplant
; 17(4): 558-65, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20674758
8.
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.
Biol Blood Marrow Transplant
; 17(9): 1343-51, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21320619
9.
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
Blood
; 114(9): 1736-45, 2009 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-19556425
10.
The role of autologous transplantation for acute myeloid leukemia in first and second remission.
Best Pract Res Clin Haematol
; 20(1): 77-84, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17336257
11.
The cancer and leukemia group B transplant committee.
Clin Cancer Res
; 12(11 Pt 2): 3635s-7s, 2006 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16740798
12.
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Lancet Haematol
; 4(9): e431-e442, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28826616
13.
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Ann N Y Acad Sci
; 1073: 465-90, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17102115
14.
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia.
J Clin Oncol
; 20(10): 2464-71, 2002 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12011123
15.
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
J Clin Oncol
; 33(35): 4167-75, 2015 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26527780
16.
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk
; 15(6): 377-83, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25776193
17.
Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Cancer Chemother Pharmacol
; 53(6): 468-74, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15138711
18.
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
Cancer Chemother Pharmacol
; 74(5): 927-38, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25163570
19.
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
J Clin Oncol
; 27(25): 4162-8, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19636009
20.
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Cancer Chemother Pharmacol
; 63(5): 859-64, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18670778